In this issue of the Archives, Le Roux-Villet et al1 describe 25 patients with mucous membrane pemphigoid (MMP) who had either extensive disease for a mean of 32 months, ie, progressive eye and/or oral/tracheal involvement or were refractory to the initially applied immunosuppressive or immunomodulatory drugs. The cohort of patients with MMP had either ocular (n = 10) and/or extraocular involvement (n = 15) and received 1 or 2 cycles of rituximab (each cycle consisting of rituximab, 4 × 375 mg/m2 administered intravenously at weekly intervals). After the first rituximab cycle, a total of 68% (17 of 25) of patients with MMP experienced complete clinical remission within 12 weeks, while an additional 5 of 25 patients required a second cycle of rituximab to achieve clinical remission. Overall, only 3 of 25 patients (12%) did not experience clinical remission with rituximab treatment. Most of the patients did not continue adjuvant immunosuppressive drugs and received only concomitant immunomodulatory treatment with dapsone or sulfasalazine during rituximab treatment. Of the 22 patients in complete remission, 10 developed a clinical relapse within 4 months, suggesting a short-lived effect of rituximab. Of note, 3 of 25 patients (12%) developed severe infections within 4 months after rituximab treatment and 2 patients died.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.